Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells
Journal Title: Global Journal of Cancer Therapy - Year 2015, Vol 1, Issue 1
Abstract
Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already responsive to eribulin, as well as inducing de novo anticancer effects in non-responders, we performed a combinatorial high throughput screen to identify drugs that combine with eribulin to selectively kill tumor cells. Among other observations, we found that inhibitors of ErbB1/ErbB2 (lapatinib, BIBW-2992, erlotinib), MEK (E6201, trametinib), PI3K (BKM-120), mTOR (AZD 8055, everolimus), PI3K/mTOR (BEZ 235), and a BCL2 family antagonist (ABT-263) show combinatorial activity with eribulin. In addition, antagonistic pairings with other agents, such as a topoisomerase I inhibitor (topotecan hydrochloride), an HSP-90 inhibitor (17-DMAG), and gemcitabine and cytarabine, were identified. In summary, the preclinical studies described here have identified several combination drugs that have the potential to either augment or antagonize eribulin’s anticancer activity. Further elucidation of the mechanisms responsible for such interactions may be important for identifying valuable therapeutic partners for eribulin.
Authors and Affiliations
Rickles Richard J, Matsui Junji, Zhu Ping, Funahashi Yasuhiro, Grenier Jill M, Steiger Janine, Zhao Nanding, Littlefield Bruce A, Nomoto Kenichi, Uenaka Toshimitsu
Keywords
Related Articles
- EP ID EP352819
- DOI 10.17352/2581-5407.000004
- Views 92
- Downloads 0
MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer
In the past few years, immunotherapy, particularly immune checkpoint inhibitors, have redefined standard of care cancer treatment for numerous malignancies. However, despite the wealth of promising data and great enthusi...
Bortezomib in Anti-Cancer Activity: A Potential Drug
26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhe...
Video Endoscopic Inguinal Lymphadenectomy: Refining surgical technique after ten years experience
Penile carcinoma is a rare malignant disease with a significantly higher incidence in some areas of under- developed countries [1]. Inguinal nodal involvement is found in 20% to 40% of cases at diagnosis and nodal metast...
An Overview of Thyroid Cancer Genetics and Inheritance
Thyroid cancer (TC) is the most common endocrine malignancy and its incidence hasbeen increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell t...
Diagnosing HPV-Related Oropharyngeal Cancers: The Need to Speak a Common Language
Oral cavity squamous cell cancer (OSCC) and Oropharynx squamous cell carcinoma (OPSCC) are the most frequent forms of Head and Neck Cancers (HNCs) [1]. About 300,000 new cases of oral cancers are being counted yearly wor...